
    
      This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study to
      evaluate the efficacy and safety of multiple-dose (7 doses) subcutaneous administration of
      benralizumab (MEDI-563) in adult subjects with uncontrolled asthma.
    
  